The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to prevent drug companies from implementing a 340B rebate model. The brief was filed in a consolidated appeal involving five drug companies. The AHA said such models from drug companies would devastate hospitals financially.  

 

“In a world of finite resources, 340B hospitals will have no choice but to divert funds away from patient services and towards burdensome compliance,” the AHA wrote. “All of these consequences ‘frustrate’ the goal of the 340B statute.” 

Authored in-house by Chad Golder, AHA general counsel, the AHA was joined in the filing by the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.

Related News Articles

Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
The Centers for Medicare & Medicaid Services Oct. 21 announced that it has instructed all Medicare Administrative Contractors to lift a hold and begin…
Headline
Medicare open enrollment for 2026 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…
Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…